A pooled retrospective analysis of data from 6 clinical trials showed a significant benefit with chemotherapy plus EGFR therapy compared to bevacizumab on overall survival (OS) in metastatic colorectal cancer (mCRC) patients with RAS wild-type and left-sided tumors1. This evidence concerns the gene EGFR and metastatic colorectal cancer.